(n = 3) and healthy volunteers (n = 3). The mean IC 50 values were 62 M and 3.3 M for MCL cells and normal lymphocytes, respectively (P = 0.0001). The 19-fold resistance of the MCL cells to the cytotoxic effects of fludarabine was consistent with the lack of clinical response to the drug. The IC 50 for malignant cells from untreated CLL patients was similar to that of normal lymphocytes (2.6 M).
3
H-Gemcitabine was used to study nucleoside drug uptake in MCL (n = 1) and normal lymphocytes (n = 3), because gemcitabine transportability by native and recombinant human nucleoside transporters has been fully defined.
2 Uptake intervals were determined at 2 s, 10 s, 10 min, and 1 h. Initial uptake rates for the 2-10 s interval were determined by linear regression. Initial uptake of 3 H-gemcitabine (mean ± s.d., in pmol/10 6 cells/s) was undetectable in the MCL cells and 0.013±0.007 in the normal lymphocytes (P = 0.01). The 1 h net accumulation, which represents multiple processes, potentially including drug uptake, metabolism and efflux, was 1.16 ± 0.48 and 11.0 ± 1.02 pmol/10 6 cell, respectively, in MCL cells and normal lymphocytes (P = 0.0001).
Because decreased cellular uptake and accumulation of gemcitabine were observed in MCL cells, we studied the relative expression of genes involved in nucleoside transport and metabolism with quantitative RT-PCR. Total RNA was extracted from the PBMC of MCL (n = 1), CLL (n = 18) and healthy volunteers (n = 3). Primers and probes designed for use with Primer Express software were purchased from PE Biosystems (Foster City, CA, USA), specific for each of four nucleoside transporters (hENT1, hENT2, hCNT1, hCNT2), dCK, and three 5′-nucleotidases (CN-II, dNT-I, ectonucleotidase). mRNA levels were then quantified by reverse transcription followed by Taqman polymerase chain reaction (PCR) using the ABI 7700 sequence detection system (Applied Biosystems). The relative amounts of each gene transcript present in RNA preparations from MCL, CLL and normal lymphocytes were compared using standard methods, normalized to GAPDH expression. 3 Relative levels of mRNA for each gene, normalized to levels of the same gene in peripheral blood lymphocytes from healthy donors, are shown in Table 1 . The levels of mRNA encoding the equilibrative transporters (hENT1 and hENT2) and two of the 5′-nucleotidase enzymes (CN-II and dNT-I) were elevated by less than 50% in MCL cells compared to normal lymphocytes. The concentrative transporters hCNT1 and hCNT2 were not detected in either cell sample. Ectonucleotidase mRNA was detected in normal lymphocytes, but not in MCL cells. dCK mRNA was three-fold higher in MCL cells than in normal lymphocytes.
The ratios of relative mRNA levels in MCL cells to a comparison cohort of 18 CLL samples are also listed in Table 1 . The levels of hENT1 mRNA were higher in MCL cells compared to CLL cells. Other differences included greater CN-II and dCK mRNA levels and lower hENT2, ectonucleotidase and dNT-I mRNA levels in MCL cells compared to CLL cells.
The sequence of hENT1 cDNA for the MCL cells was identical to the published sequence (Genbank database entry U81375, www.ncbi.nlm.nih.gov), 4 ruling out mutation in the coding regions of hENT1 as a mediator of this patient's drug resistance.
MCL comprises 2.5-9% of B cell lymphomas. 5 The majority present with stage III-IV disease, and have the worst long-term overall survival For each protein, the relative abundance of mRNA in normal lymphocytes was defined as unity. Data are presented for a single MCL patient and 18 CLL patients, and values represent the mean ± the standard deviation of experiments performed in triplicate.
rates (Ͻ10%) of all the major B cell lymphomas. 6 The use of nucleoside analogues for MCL has been limited, and most patients in these series 5 have been pre-treated with other agents. Response rates range from 11 to 53%, and are substantially shorter and less frequent than those seen in other indolent lymphomas or CLL. 5 Cell-cycle dysregulation or defects in apoptosis pathways have been found in MCL, and may be implicated in the drug resistance seen in this disease. 7 Given the resistance of our patient's malignancy to a broad array of therapies with varying mechanisms of action, such mechanisms are probably relevant. However, our patient exhibited clinical and ex vivo resistance to fludarabine, associated with a ninefold reduction in nucleoside drug accumulation compared to that of normal circulating lymphocytes. These MCL cells were functionally nucleoside transport deficient, as uptake of gemcitabine was undetectable during short exposures (2-10 s) and very low during long exposures (1 h) to 3 H-gemcitabine. We therefore propose inefficient intracellular accumulation as an important mechanism of the nucleoside drug resistance observed in this case.
The observed gene expression profile in the MCL cells included abundant hENT1 and dCK expression, and only minimal increases in some 5′-nucleotidases relative to CLL and normal lymphocytes. Furthermore, the cDNA sequence of hENT1 was identical to the published sequence, ruling out mutation in the coding regions of hENT1 as the cause of the reduced drug accumulation. We conclude that the expression of the genes assessed in this report did not explain the observed nucleoside transport deficiency and nucleoside chemoresistance. Potentially, aberrant production of nucleoside transporters and/or metabolic enzymes downstream of transcription, ie alterations in RNA processing, translation, or post-translational modification, could explain the observed deficiency in nucleoside transport and accumulation.
It is also possible that genes other than those that were studied in this case were involved in the poor drug uptake and efficacy that was observed. Two members of the ATP-binding cassette transporter protein family have recently been found to mediate nucleotide analogue efflux from cells. MRP4 and MRP5 have been implicated in resistance to nucleoside analogues by means of nucleoside monophosphate efflux, 8 but have not been shown to mediate anticancer nucleotide efflux. The role of these proteins in clinical resistance to nucleoside chemotherapy warrants investigation.
In summary, we report the first studies of nucleoside drug uptake and accumulation in mantle cell neoplasia. The patient's malignancy exhibited clinical resistance to fludarabine chemotherapy, and in vitro fludarabine insensitivity. Deficiency in both initial nucleoside uptake and subsequent accumulation suggest that alterations in the early steps of nucleoside transport and/or metabolism contributed to resistance. The quantitative expression profile of eight genes involved in nucleoside analogue uptake and metabolism did not identify major changes at mRNA levels, suggesting that the mechanism of reduced nucleoside drug uptake was downstream of gene transcription or involved other genes. Ongoing studies of the expression and function of the protein products of these genes will further clarify their role in clinical nucleoside chemotherapy resistance.
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